BLU / Bellus Health (BLU) Reports Q3 Loss, Misses Revenue Estimates

BELLUS Health Inc (TSX:BLU) said its shareholders overwhelmingly have approved a US$2 billion takeover by GSK PLC (LSE:GSK, NYSE:GSK). The late-stage more_horizontal

Bellus' lead therapy, camlipixant, is being tested against refractory chronic cough. The company is a clinical-stage biotech with no marketed therapie more_horizontal

11:55am: Bellus Health (TSX:BLU), The Lion Electric Company shares make big gains  BELLUS Health Inc (Bellus Health (TSX:BLU)) shares shot up 99% t more_horizontal

BELLUS Health and GSK have agreed on a $2 billion buyout agreement. Through this deal, GSK will acquire a late-stage chronic cough medication that cou more_horizontal

GSK added to a series of recent takeovers Tuesday with the $2 billion acquisition of Bellus Health. But BLU stock and GSK stock diverged. more_horizontal

GSK PLC said Tuesday that it has reached an agreement to buy the late-stage biopharmaceutical company Bellus Health Inc. BLU, +3.08% BLU, +2.83% for $ more_horizontal

The mean of analysts' price targets for Bellus (BLU) points to a 156% upside in the stock. While this highly sought-after metric has not proven reason more_horizontal

Refractory chronic cough remains as a complex condition that requires a medical breakthrough for treatment. BELLUS Health Inc. is pushing ahead on thi more_horizontal